You interpretation is that they received something from the data...

You interpretation is that they received something from the data monitoring committee yesterday afternoon recommending that the trial be pulled for efficacy . Because of continuous disclosure they immediately suspended the stock and this has given them the time to go and negotiate with the fda on the basis of an accelerated approval for COVID 19 . It cant be either stopping the trial for lack of efficacy or a recommendation to carry on as that would not need a suspension . The timing fits very well with when the 60percent cohort was meant to go through thirty days . Going to be very interesting , if true , with the fda as they are going to have egg on their face with respect to gvhd as you would have thought that efficacy is v v similar to ards.